Bioresponsive Protein Nanotherapeutics for Lung Cancer Treatment
Abstract
Lung cancer is the leading cause of cancer-related death, and is an urgent priority among veterans - not only is the incidence higher, but also the survival is lower than in civilian populations (according to the Lung Cancer Alliance). Lung cancer is also a cause of concern for current active military due to exposure to respiratory carcinogens and to increased incidence of smoking among active military, especially among those deployed to combat arenas. More studies are thus highly needed for identifying new therapeutic strategies for better treatment of lung cancer. This project aims to develop an innovative protein-based nanomedicine for lung cancer therapy, and is directly relevant to one of the LCRP Areas of Emphasis: “Identify innovative strategies for prevention and treatment of early and/or localized lung cancer”. One significant challenge in protein-based cancer therapy is the low efficiency of delivering therapeutic proteins into tumor cells. Our project proposes a unique nanotechnology to address this issue. The successful completion of this project will have a profound impact in expanding the clinical application of protein therapies in cancer patients, and this strategy could be further combined with other therapies (e.g., chemotherapy and immunotherapy) for more effective lung cancer treatment.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Oct 29, 2018
- Source ID
- W81XWH1810392
Entities
People
- Jinjun Shi
Organizations
- United States Army